US OptionsDetailed Quotes

ESPR241220P5500

Watchlist

2.95
0.000.00%

15min DelayClose Dec 13 16:00 ET

0.00High0.00Low

Esperion Therapeutics Stock Discussion

10xStockPicks

2 minutes ago

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

10xStockPicks

14 minutes ago

Must BUY Esperion Therapeutics Selling FDA Approved Statin Alternative Drugs Will Soon Be Acquired Suspect The Analysts.

10xStockPicks

7 hours ago

Esperion Is An Acquisition Target. Very Favorable New Debt Terms For Investors Offers Excellent Buying Opportunity 10x Upside Potential. Profitable in 2025.

$Esperion Therapeutics (ESPR.US) is the only pharmaceutical company with statin alternative medications Nexletol & Nexlizet for primary prevention with compounding monthly script growth in a massive market space, 21M Americans need statin alternative medications, either due to statin intolerance or need additional LDLC lowering. ESPR now...

AB84

Dec 13 09:10

Hold

$Esperion Therapeutics (ESPR.US)$ 10 bagger one of these days

UnluckyDog

Dec 13 08:13

$Esperion Therapeutics (ESPR.US)$
gone for good ? 😢

DazzlerAus

Dec 12 08:35

$Esperion Therapeutics (ESPR.US)$

Jaguar8

Dec 12 07:07

NEWS

$Esperion Therapeutics (ESPR.US)$
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics (NASDAQ: ESPR) has entered into a licensing agreement with Neopharm Israel for exclusive commercialization rights of NEXLETOL® and NEXLIZET® in Israel. The agreement includes an upfront payment, near-term milestone payments, and tiered royalties on product sales.
Under the agreement terms, Neopharm will rece...

Trytosaveabit

Dec 12 07:02

Update

$Esperion Therapeutics (ESPR.US)$ Reuters
1 min ago
Esperion Partners With Neopharm to Commercialize Nexletol® (Bempedoic Acid) and Nexlizet® (Bempedoic Acid and Ezetimibe) in Israel! Esperion Therapeutics Inc: Under Terms of Agreement, Esperion Will Receive an Upfront and Near-Term Milestone Payments

936998268

Dec 11 10:06

$Esperion Therapeutics (ESPR.US)$ Best buy in is when it reach USD2

Noah sigma

Dec 11 09:00

$Esperion Therapeutics (ESPR.US)$ wjy is thus happening

No comment yet